Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Trends And Growth Drivers Point To Strong Future Potential
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market CAGR Analysis And Future Market Development
Between 2025 and 2026, the investigational new drug contract development and manufacturing organization (CDMO) market is projected to expand from $5.91 billion to $6.33 billion, reflecting a compound annual growth rate (CAGR) of 7.1%. This strong growth in recent years has been driven by a scarcity of CDMOs specializing in investigational drugs, heightened demand for small molecule synthesis, continued dependence on traditional manufacturing services, rising numbers of clinical trials, and early uptake of regulatory support offerings.
The investigational new drug contract development and manufacturing organization (CDMO) market is projected to experience significant expansion over the coming years. By 2030, it is anticipated to reach a valuation of $8.17 billion, reflecting a compound annual growth rate (CAGR) of 6.6%. This forecasted growth is driven by several key factors, including the expansion of capabilities for gene and cell therapy manufacturing, heightened demand for monoclonal antibodies and recombinant proteins, investments in cutting-edge formulation technologies, the embrace of scalable manufacturing platforms, and strengthened global biotechnology research partnerships. Notable developments shaping this period include a surge in demand for services related to early-stage drug development, a rise in clinical trial material supply offerings, a growing emphasis on meeting regulatory and quality benchmarks, the broadening of biologics and advanced therapy development, and the adoption of bespoke manufacturing solutions for both small and large molecules.
Download A Free Sample Report For Comprehensive Market Insights:
Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Industry Drivers: What Is Driving Revenue Growth?
The projected expansion of the investigational new drug contract development and manufacturing organization (CDMO) market is expected to be driven by the increasing number of clinical trials. These trials are meticulously structured studies conducted with human volunteers to evaluate the safety and effectiveness of medical treatments, procedures, or interventions under regulated conditions. The growing need for novel therapies, spurred by rising rates of chronic and complex illnesses, is primarily fueling the surge in clinical trials, as pharmaceutical and biotech companies work to develop and test new therapeutic options. By optimizing the development and manufacturing of formulations ready for trials, investigational new drug CDMOs play a key role in supporting these studies, guaranteeing a timely and regulatory-compliant supply of investigational products for every stage of the research. For example, as reported in December 2024 by the Association of the British Pharmaceutical Industry, a trade association for the UK pharmaceutical sector, the total number of industry-initiated clinical trials in the United Kingdom grew from 411 in 2022 to 426 in 2023. Additionally, Phase III trial initiations saw a 16.5% increase over the same timeframe, moving from 182 to 212. Consequently, the growth of the investigational new drug contract development and manufacturing organization (CDMO) market is being propelled by the escalating volume of clinical trials.
Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Segments: Where Are The Largest Growth Opportunities?
The investigational new drug contract development and manufacturing organization (cdmo) market covered in this report is segmented –
1) By Product: Small Molecules, Large Molecules
2) By Formulation Type: Solid Formulations, Liquid Formulations, Injectable Formulations
3) By Service Type: Clinical Trial Material Supply, Regulatory Support Services, Manufacturing Services
4) By End-User: Biotechnology Companies, Academic And Research Institutes, Other End-Users
Subsegments:
1) By Small Molecules: Synthetic Small Molecules, Semi-synthetic Small Molecules, Peptide-based Small Molecules, Oligonucleotides
2) By Large Molecules: Monoclonal Antibodies (mAbs), Recombinant Proteins, Vaccines, Cell Therapy Products, Gene Therapy Products, RNA-based Therapeutics
Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Growth Trends: What Is Influencing The Future Outlook?
Key industry players in the investigational new drug contract development and manufacturing organization (CDMO) market are actively forming strategic partnerships to improve their development capabilities and accelerate clinical-stage entry. These partnerships are defined as formal collaborations between two or more organizations that work together to achieve common goals by combining their strengths, resources, or expertise for mutual advantage while retaining their separate identities. To illustrate, in August 2023, Sartorius AG, a life science firm based in Germany, formed an alliance with Repligen Corporation, a US-based life sciences company, to introduce a combined system that integrates BIOSTAT STR and XCell ATF technologies for upstream process intensification. The purpose of this partnership is to streamline biopharmaceutical production through improved efficiency and scalability. This effort represents a step forward in Sartorius’ ongoing innovation with bioprocessing solutions, underscoring its dedication to advancing the biomanufacturing sector.
Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Major Participants And Competitive Dynamics
Major companies operating in the investigational new drug contract development and manufacturing organization (cdmo) market are Thermo Fisher Scientific Inc., Fresenius Kabi AG, Lonza Group Ltd., Catalent Inc., Samsung Biologics Co. Ltd., Fareva SA, Recipharm AB, PCI Pharma Services, Vetter Pharma, Delpharm, Kindeva Drug Delivery LP, Ajinomoto Bio-Pharma Services, Cenexi SAS, Grand River Aseptic Manufacturing Inc., INCOG BioPharma Services, Aurigene Pharmaceutical Services, Jubilant HollisterStier LLC, Symbiosis Pharmaceutical Services Ltd., Afton Scientific Corp., Amaran Biotech Inc.
Access The Complete Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Report:
Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the investigational new drug contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the investigational new drug contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
